About Us

ImmuneID is transforming precision immunology by combining our proprietary aiSPIRE platform with advanced bioinformatics and expertise in immune system biology.

We aim to create novel, transformational therapies through powerful next-generation sequencing and robust protein display technologies to comprehensively characterize patient antibody interactions in immune diseases. Our platform rapidly screens billions of antibody-target interactions to build a map of human immunity. Through a combination of bench science, insightful computational biology and big data generation, ImmuneID seeks to improve and personalize patient diagnoses to deliver precise treatments for immune-mediated diseases.

Founded in late 2020 by Longwood Fund, we are backed by top-tier biotechnology venture investors including Alexandria Venture Investments, Alta Partners, Arch Venture Partners, In-Q-Tel, Pitango Healthtech Fund, Section 32, Tekla Capital Management and Xfund.

Leadership

BOARD

SAB

INVESTORS

Our Team

James S. Scibetta

CEO

Annalisa D’Andrea, PhD

President and CSO

Jeff Capello

CFO/COO

Rob Hadfield

Acting General Counsel

Jeremiah Degenhardt, PhD

Senior Vice President, Computational Biology

Alexandra Joseph, PhD

Vice President, Research

Our Board of Directors

Christoph Westphal,
MD, PhD

Chair, ImmuneID BOD
Partner, Longwood Fund

Ittai Harel

ImmuneID BOD
Managing Partner, Pitango Healthtech Fund

Peter Hutt

ImmuneID BOD
Senior Counsel, Covington & Burling LLP

Dan Janney

ImmuneID BOD
Managing Partner, Alta Partners

Steve Kafka, PhD

ImmuneID BOD
Managing Partner, Section 32

James S. Scibetta

CEO and Director

Our Founders and Advisors

Steve Elledge, PhD

Co-founder, ImmuneID

Tomasz Kula, PhD

Co-founder, ImmuneID

H. Benjamin Larman, PhD

Co-founder, ImmuneID

Michael Mina, MD PhD

SAB, ImmuneID

David Walt PhD

Advisor, ImmuneID

Investors

Contact Us

275 Second Ave, Suite 100
Waltham, MA 02451
info@immuneidrx.com

©2022 ImmuneID, Inc.
Privacy Policy Terms of Service

Christoph Westphal, PhD

ImmuneID Chair and Partner, Longwood Fund

Dr. Westphal is co-founder and General Partner of Longwood Fund and has spent 20 years as a biotech CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of seven biotechnology companies that have completed initial public offerings (IPOs) and created sustained market value of over $40 billion and have developed and received FDA approval for over 10 important drugs. These include: Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, acquired by J&J in 2020), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Inc. (NASDAQ: XLRN, acquired by Merck in 2021), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), Verastem (NASDAQ: VSTM), and TScan Therapeutics (NASDAQ: TCRX). Dr. Westphal is also co-founder of Alnara Pharmaceuticals (acquired by Eli Lilly in 2010); co-founder/former CEO of DEM Bio Pharma, co-founder/Chair of ImmuneID; co-founder/former CEO/Chair of Immunitas Therapeutics; co-founder of Pyxis Oncology (NASDAQ: PYXS); and co-founder of Concert Pharmaceuticals (NASDAQ: CNCE). Companies founded by Dr. Westphal have created thousands of jobs in the Boston area.

Companies founded by Dr. Westphal and Longwood partners have founded over 20 biotech companies, received FDA approval for over 20 important drugs, including the first RNAi therapy; for currently incurable cancers; the largest-selling heparin in the United States; a therapy for MS; for Beta Thalassemia and Myelodysplastic Syndrome; and several experimental medicines: for cystic fibrosis (phase 3); for serious inflammatory disorders (phase 2), and created sustained market caps of over $100 billion.

Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University; and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has served or currently serves as a member or director of: the Boston Commercial Club, the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board, the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra; he is also a member of the ownership group of the Boston Celtics. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in journals such as Cell, Nature, and Nature Genetics. Dr. Westphal has been featured on 60 Minutes with Morley Safer, CNN’s Vital Signs with Dr. Sanjay Gupta, an ABC News Special hosted by Barbara Walters, and as the subject of Fortune, New York Times, and Wall Street Journal cover articles. Dr. Westphal has generally avoided media interviews since 2010.